{"entity":{"id":"toremifene","kind":"drug","name":"Toremifene","aka":[],"tldr":"Toremifene (Fareston) is a tamoxifen-like tablet for postmenopausal women with hormone-sensitive breast cancer that has spread.","summary":"Toremifene was approved by the FDA in May 1997 for metastatic breast cancer in postmenopausal women with oestrogen receptor-positive or unknown tumours, on three randomised trials (North American, Eastern European and Nordic) that showed response rates and time to progression similar to tamoxifen; the EU authorised Fareston in 1996 for first-line hormonal treatment of hormone-dependent metastatic breast cancer. It never displaced tamoxifen and aromatase inhibitors then moved ahead of both. QT prolongation carries a boxed warning; hot flushes, sweating and vaginal discharge are the common effects, with thromboembolism and endometrial changes as class risks.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Toremifene","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=toremifene"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/toremifene"},{"label":"EPAR","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/fareston"}],"tags":["nci-list"],"related":["tamoxifen"],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":["estrogen-receptor"],"drugs":[],"companies":["kyowa-kirin","gtx"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00129142","nct03351062","nct02132390"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Fareston","modality":"Selective oestrogen receptor modulator (triphenylethylene)","mechanism":"Chlorinated tamoxifen analogue that binds the oestrogen receptor and acts as an antagonist in breast tissue with partial agonist effects elsewhere.","approvals":[{"region":"US","year":1997,"indication":"Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumours"},{"region":"EU","year":1996,"indication":"First-line hormonal treatment of hormone-dependent metastatic breast cancer in postmenopausal women"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/toremifene/","neighbours":{"drug":[{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"company":[{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/"},{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/"}],"trial":[{"id":"nct02132390","kind":"trial","name":"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea","route":"/trials/nct02132390/"},{"id":"nct03351062","kind":"trial","name":"Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer","route":"/trials/nct03351062/"},{"id":"nct00129142","kind":"trial","name":"Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy","route":"/trials/nct00129142/"}]}}